Stock listing
Hanover:19T Idorsia Ltd. Aktie
German listing (Hanover) of Idorsia Ltd. · home listing SIX Swiss:IDIA
Follow Idorsia Ltd. into a list and get an email when it puts out news.
Home listing price · SIX:IDIA
3.59 CHF -0.25 (-6.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, SIX:IDIA
- Day range
- 3.53 – 3.72 CHFNov 20, 2026
- Volume
- 783,165 sharesNov 20, 2026
- Market cap
- 967.4M CHFAt the close on Nov 20, 2026 · price × 269.8M shares outstanding
- 52-week range
- 2.80 – 7.56 CHFLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 4.33M CHFMedian day 743,681 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| SIX Swiss:IDIA · Home | 3.586 CHF | -0.254 (-6.6%) | 783,165 | 3.71 | 3.72 | 3.53 | 3.84 | Close on Nov 20, 2026 |
| OTC:IDRSF | $4.20 USD | -0.50 (-10.6%) | 300 | $4.20 | $4.20 | $4.20 | $4.70 | Close on Nov 20, 2026 |
| Frankfurt:19T | €3.926 EUR | -0.366 (-8.5%) | — | €3.988 | €3.988 | €3.926 | €4.292 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SIX:IDIA · CHF, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 3.586 | -0.254 | -6.6% | 3.71 | 3.72 | 3.53 | 783,165 | |
| 3.84 | -0.13 | -3.3% | 3.958 | 3.98 | 3.82 | 315,324 | |
| 3.97 | -0.01 | -0.3% | 3.94 | 4.06 | 3.878 | 705,754 | |
| 3.98 | +0.072 | +1.8% | 3.86 | 4.042 | 3.86 | 1,064,432 | |
| 3.908 | -0.042 | -1.1% | 3.888 | 3.948 | 3.86 | 680,029 | |
| 3.95 | -0.064 | -1.6% | 4.014 | 4.05 | 3.802 | 1,393,304 | |
| 4.014 | -0.112 | -2.7% | 4.162 | 4.17 | 3.978 | 1,121,328 | |
| 4.126 | -0.028 | -0.7% | 4.20 | 4.224 | 4.11 | 344,005 | |
| 4.154 | +0.096 | +2.4% | 4.096 | 4.17 | 4.076 | 463,521 | |
| 4.058 | -0.142 | -3.4% | 4.132 | 4.132 | 3.99 | 997,202 | |
| 4.20 | -0.21 | -4.8% | 4.444 | 4.446 | 4.164 | 1,003,263 | |
| 4.41 | +0.078 | +1.8% | 4.468 | 4.488 | 4.27 | 853,235 | |
| 4.332 | +0.078 | +1.8% | 4.186 | 4.434 | 4.136 | 745,001 | |
| 4.254 | -0.216 | -4.8% | 4.466 | 4.47 | 4.178 | 1,173,910 | |
| 4.47 | -0.112 | -2.4% | 4.568 | 4.576 | 4.43 | 640,440 | |
| 4.582 | -0.01 | -0.2% | 4.368 | 4.624 | 4.262 | 1,157,486 | |
| 4.592 | +0.04 | +0.9% | 4.50 | 4.64 | 4.41 | 553,848 | |
| 4.552 | +0.212 | +4.9% | 4.40 | 4.57 | 4.364 | 732,390 | |
| 4.34 | +0.152 | +3.6% | 4.37 | 4.43 | 4.28 | 793,373 | |
| 4.188 | -0.048 | -1.1% | 4.246 | 4.246 | 4.122 | 364,227 | |
| 4.236 | -0.03 | -0.7% | 4.262 | 4.264 | 4.08 | 551,824 | |
| 4.266 | +0.022 | +0.5% | 4.25 | 4.30 | 4.212 | 350,763 | |
| 4.244 | +0.062 | +1.5% | 4.118 | 4.30 | 4.108 | 653,657 | |
| 4.182 | +0.082 | +2.0% | 4.03 | 4.182 | 3.992 | 629,570 | |
| 4.10 | -0.098 | -2.3% | 4.22 | 4.222 | 4.032 | 811,026 | |
| 4.198 | -0.038 | -0.9% | 4.18 | 4.222 | 4.132 | 742,360 | |
| 4.236 | +0.204 | +5.1% | 4.05 | 4.248 | 4.02 | 644,397 | |
| 4.032 | -0.368 | -8.4% | 4.25 | 4.308 | 4.032 | 1,460,523 | |
| 4.40 | +0.202 | +4.8% | 4.29 | 4.432 | 4.252 | 769,980 | |
| 4.198 | +0.148 | +3.7% | 4.134 | 4.198 | 3.932 | 1,213,731 | |
| 4.05 | -0.286 | -6.6% | 4.284 | 4.284 | 4.05 | 1,361,055 | |
| 4.336 | -0.064 | -1.5% | 4.354 | 4.376 | 4.202 | 739,217 | |
| 4.40 | -0.068 | -1.5% | 4.60 | 4.648 | 4.298 | 1,464,480 | |
| 4.468 | +0.01 | +0.2% | 4.47 | 4.51 | 4.37 | 608,362 | |
| 4.458 | -0.104 | -2.3% | 4.514 | 4.596 | 4.45 | 656,402 | |
| 4.562 | -0.084 | -1.8% | 4.638 | 4.696 | 4.508 | 793,660 | |
| 4.646 | +0.208 | +4.7% | 4.468 | 4.646 | 4.404 | 736,536 | |
| 4.438 | +0.058 | +1.3% | 4.414 | 4.574 | 4.368 | 917,350 | |
| 4.38 | -0.058 | -1.3% | 4.438 | 4.492 | 4.334 | 940,999 | |
| 4.438 | +0.076 | +1.7% | 4.406 | 4.438 | 4.36 | 1,259,715 | |
| 4.362 | -0.206 | -4.5% | 4.55 | 4.576 | 4.348 | 2,084,039 | |
| 4.568 | -0.168 | -3.5% | 4.75 | 4.832 | 4.568 | 1,345,837 | |
| 4.736 | -0.06 | -1.3% | 4.80 | 4.876 | 4.724 | 923,237 | |
| 4.796 | -0.04 | -0.8% | 4.812 | 4.848 | 4.75 | 697,364 | |
| 4.836 | -0.064 | -1.3% | 4.94 | 5.04 | 4.81 | 7,781,564 | |
| 4.90 | -0.05 | -1.0% | 5.00 | 5.04 | 4.88 | 581,978 | |
| 4.95 | +0.192 | +4.0% | 4.782 | 4.952 | 4.752 | 737,733 | |
| 4.758 | -0.24 | -4.8% | 4.906 | 5.05 | 4.60 | 1,186,721 | |
| 4.998 | -0.002 | 0.0% | 4.95 | 5.075 | 4.886 | 711,884 | |
| 5.00 | -0.02 | -0.4% | 5.03 | 5.11 | 4.952 | 501,849 | |
| 5.02 | -0.095 | -1.9% | 5.18 | 5.205 | 5.015 | 387,585 | |
| 5.115 | -0.01 | -0.2% | 5.08 | 5.165 | 5.035 | 317,644 | |
| 5.125 | +0.045 | +0.9% | 5.195 | 5.20 | 4.98 | 377,488 | |
| 5.08 | +0.084 | +1.7% | 4.98 | 5.105 | 4.96 | 661,462 | |
| 4.996 | -0.174 | -3.4% | 5.17 | 5.205 | 4.996 | 500,681 | |
| 5.17 | -0.025 | -0.5% | 5.265 | 5.40 | 5.17 | 493,383 | |
| 5.195 | +0.11 | +2.2% | 5.085 | 5.39 | 5.085 | 909,892 | |
| 5.085 | +0.145 | +2.9% | 4.938 | 5.085 | 4.90 | 887,960 | |
| 4.94 | -0.395 | -7.4% | 5.25 | 5.30 | 4.94 | 2,491,922 | |
| 5.335 | -0.415 | -7.2% | 5.745 | 5.82 | 5.335 | 991,694 | |
| 5.75 | +0.075 | +1.3% | 5.67 | 5.88 | 5.67 | 644,450 | |
| 5.675 | +0.105 | +1.9% | 5.585 | 5.765 | 5.585 | 674,046 | |
| 5.57 | +0.195 | +3.6% | 5.44 | 5.595 | 5.40 | 594,248 | |
| 5.375 | -0.175 | -3.2% | 5.50 | 5.505 | 5.275 | 856,356 | |
| 5.55 | -0.05 | -0.9% | 5.55 | 5.63 | 5.38 | 948,671 | |
| 5.60 | -0.19 | -3.3% | 5.90 | 6.00 | 5.53 | 861,214 |
- Ticker
- Hanover:19T
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Hanover
- Currency
- EUR
What changed lately
Latest news release · Oct 29, 2026
Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance
Latest earnings call · Jul 30, 2026
Idorsia (SIX Swiss: IDIA) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Investor Presentation (November 2026)
Investor deck · 31 slides
Latest news
Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance
Oct 29, 2026
Closed 4.58 (-0.2%) on Oct 29, 2026
Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialists
Oct 29, 2026
Closed 4.58 (-0.2%) on Oct 29, 2026
Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera
Oct 28, 2026
Closed 4.59 (+0.9%) on Oct 28, 2026
Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026
Oct 23, 2026
Closed 4.34 (+3.6%) on Oct 26, 2026
Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V
Aug 11, 2026
Closed 6.51 (+9.7%) on Aug 11, 2026
QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth
Jul 30, 2026
Closed 6.21 (-5.0%) on Jul 30, 2026
Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant
Jul 27, 2026
Closed 6.63 (+7.5%) on Jul 27, 2026
Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call
Jul 23, 2026
Closed 6.17 (+1.5%) on Jul 24, 2026
Idorsia appoints Roland Wandeler as Chief Executive Officer
Jul 1, 2026
Closed 6.61 (-3.8%) on Jul 1, 2026
Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility
Jun 26, 2026
Closed 6.86 (+14.0%) on Jun 26, 2026
Idorsia Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 33 in the last 12 months · 76 in all · newest Oct 29, 2026 · oldest 2025
- Calls
- 16 calls with a replay · 16 with a transcript · latest Jul 30, 2026
- Decks
- 55 decks · latest Nov 4, 2026
Where Idorsia Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| SIX Swiss:IDIA · Home listing | SIX Swiss | Switzerland | CHF |
| LSIN:0RQE | LSIN | United Kingdom | CHF |
| OTC:IDRSF | OTC | United States | USD |
| Lang & Schwarz:A2DTEB | Lang & Schwarz | Germany | EUR |
| gettex:19T | gettex | Germany | EUR |
| LS Exchange:A2DTEB | LS Exchange | Germany | EUR |
| BX Swiss:19T | BX Swiss | Switzerland | CHF |
| Tradegate:19T | Tradegate | Germany | EUR |
| Aquis:IDIAZ | Aquis | United Kingdom | CHF |
| Frankfurt:19T | Frankfurt | Germany | EUR |
| Turquoise:IDIAZ | Turquoise | United Kingdom | CHF |
| Dusseldorf:19T | Dusseldorf | Germany | EUR |
| Hamburg:19T | Hamburg | Germany | EUR |
| Munich:19T | Munich | Germany | EUR |
| Stuttgart:19T | Stuttgart | Germany | EUR |
| Hanover:19T · This page | Hanover | Germany | EUR |
| Xetra:19T | Xetra | Germany | EUR |
Valuation
EV/sales 10.2× against a median of 2.7×: the highest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 2.24B CHF
- P/E
- Loss
- EV/sales
- 10.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 79.2%
- Operating margin
- −106.5%
- Net margin
- −128.8%
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Idorsia Ltd. · SIX:IDIA | US$1.15B | US$2.66B | n/a | 10.2× | n/a | n/a | −128.8% | n/a | n/a |
| Zhejiang Xianju Pharmaceutical Co., Ltd. Class A · SZSE:002332 | US$1.24B | US$1.08B | 17.7× | 1.9× | n/a | 1.4× | 12.0% | 0.0× | n/a |
| Amphastar Pharmaceuticals, Inc. · NASDAQ:AMPH | US$1.20B | US$976.8M | 12.2× | 1.3× | 5.6× | 1.5× | 13.3% | 0.0× | 0.52 |
| Hualan Biological Vaccine Inc. Class A · SZSE:301207 | US$1.16B | US$845.9M | 167× | 8.1× | n/a | 1.5× | 6.6% | 0.0× | n/a |
| Chongqing Lummy Pharmaceutical Co., Ltd. Class A · SZSE:300006 | US$1.15B | US$1.04B | n/a | 9.6× | n/a | 4.5× | −16.6% | 0.1× | n/a |
| Harrow, Inc. · NASDAQ:HROW | US$1.14B | US$1.36B | n/a | 4.5× | 188× | 39.1× | −9.4% | 10.0× | 1.31 |
| Changzhou Qianhong Bio-Pharma Co., Ltd. Class A · SZSE:002550 | US$1.12B | US$929.9M | 32.3× | 4.1× | n/a | 2.7× | 15.3% | 0.0× | n/a |
| GC Biopharma Corp. · KRX:006280 | US$1.10B | US$1.30B | n/a | 0.9× | 13.2× | 1.2× | −2.5% | 0.3× | n/a |
| Vetoquinol SA · EURONEXT:VETO | US$1.09B | US$848.8M | 17.4× | 1.5× | 7.0× | 1.6× | 10.9% | 0.0× | n/a |
| North China Pharmaceutical Company Ltd. Class A · SSE:600812 | US$1.09B | US$1.55B | 81.1× | 1.3× | n/a | 1.3× | 1.1% | 0.8× | n/a |
| Basilea Pharmaceutica AG · SIX:BSLN | US$1.07B | US$964.4M | 22.4× | 3.5× | 15.2× | 5.6× | 17.3% | 0.5× | n/a |
| Median of the others | US$1.13B | US$1.01B | 22.4× | 2.7× | 13.2× | 1.6× | 8.8% | 0.0× | 0.92 |
Forecasts
Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.00 CHF · Analysts' mean
- EPS, year to Dec 2026
- -0.13 · 1 analyst
- Revenue, year to Dec 2026
- 223.3M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Roland Wandeler | Chief Executive Officer |
| Arno Groenewoud | Executive Vice President, Chief Financial Officer |
| Julien Gander | Executive Vice President, Chief Legal & Corporate Development Officer |
| Kevin Boss | Director, Investor Relations |
| Amer Joseph | Executive Vice President, Chief Medical Officer & Head of Global Clinical Development |
| Benjamin Limal | Executive Vice President, President of Europe & International Markets Region |
| Dominique Le Terrier | Executive Vice President, Head of Global Commercial Strategy & New Product Planning |
| Martine Clozel | Executive Vice President, Chief Scientific Officer & Head of Research |
Board
| Director | Role |
|---|---|
| Jean-Paul Clozel | Chairman of the Board |
| Mathieu Simon | Vice-Chairman and Lead Independent Director |
Events
- Next results
- Feb 25, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Idorsia (SIX Swiss: IDIA) Q2 2026 Earnings Call | Thu, Jul 30, 2026 · 9:00 AM ET | Replay |
| Idorsia (SIX Swiss: IDIA) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 8:00 AM ET | Replay |
| Idorsia (SIX Swiss: IDIA) Q2 2025 Earnings Call | Wed, Jul 30, 2025 · 8:00 AM ET | Replay |
| Idorsia (SIX Swiss: IDIA) Q4 2024 Earnings Call | Tue, Mar 04, 2025 · 8:00 AM ET | Replay |
| Idorsia (SIX Swiss: IDIA) Q2 2024 Earnings Call | Thu, Jul 25, 2024 · 8:00 AM ET | Replay |
| Idorsia (SIX Swiss: IDIA) Q4 2023 Earnings Call | Tue, May 21, 2024 · 8:00 AM ET | Replay |
| Idorsia (SIX Swiss: IDIA) Q3 2023 Earnings Call | Tue, Oct 24, 2023 · 8:00 AM ET | Replay |
| Idorsia (SIX Swiss: IDIA) Q2 2023 Earnings Call | Tue, Jul 25, 2023 · 9:00 AM ET | Replay |
| Idorsia (SIX Swiss: IDIA) Q1 2023 Earnings Call | Tue, Apr 25, 2023 · 2:00 AM ET | Replay |
| Idorsia (SIX Swiss: IDIA) Q4 2022 Earnings Call | Tue, Feb 07, 2023 · 3:00 PM ET | Replay |
All 16 calls
| Call | When | Status |
|---|---|---|
| Idorsia (SIX Swiss: IDIA) Q3 2022 Earnings Call | Tue, Oct 25, 2022 · 1:00 AM ET | Replay |
| Idorsia (SIX Swiss: IDIA) Q2 2022 Earnings Call | Tue, Jul 26, 2022 · 3:00 PM ET | Replay |
| Idorsia (SIX Swiss: IDIA) Q4 2021 Earnings Call | Tue, Feb 08, 2022 | Replay |
| Idorsia (SIX Swiss: IDIA) Q2 2021 Earnings Call | Wed, Jul 28, 2021 | Replay |
| Idorsia (SIX Swiss: IDIA) Q4 2020 Earnings Call | Fri, Feb 05, 2021 | Replay |
| Idorsia (SIX Swiss: IDIA) Q2 2020 Earnings Call | Thu, Jul 23, 2020 | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 28, 2026 · After close | −0.2% |
| Q2 2026 | Jul 29, 2026 · After close | −5.0% |
| Q1 2026 | Apr 28, 2026 · Before open | +4.8% |
| Q4 2025 | Feb 26, 2026 · Before open | +5.3% |
| Q3 2025 | Oct 30, 2025 · Before open | −1.6% |
| Q2 2025 | Jul 28, 2025 · After close | −4.9% |
| Q1 2025 | Apr 30, 2025 · Before open | +8.9% |
| Q4 2024 | Feb 5, 2025 · Before open | −4.3% |
| Q3 2024 | Oct 29, 2024 · Before open | +0.8% |
| Q2 2024 | Jul 25, 2024 · Before open | +18.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 21, 2024 · Before open | −2.0% |
| Q4 2023 | Mar 20, 2024 · After close | −6.8% |
| Q3 2023 | Oct 24, 2023 · Before open | −13.1% |
| Q2 2023 | Jul 25, 2023 · Before open | −5.7% |
| Q1 2023 | Apr 25, 2023 · Before open | −7.0% |
| Q4 2022 | Feb 7, 2023 · Before open | −8.9% |
| Q3 2022 | Oct 25, 2022 · Before open | +4.0% |
| Q2 2022 | Jul 26, 2022 · Before open | +0.6% |
| Q1 2022 | Apr 26, 2022 · Before open | −4.2% |
| Q4 2021 | Feb 8, 2022 · Before open | −4.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 31 slides | Nov 4, 2026 |
| Sleep Europe 2026 | Conference | 22 slides | Oct 23, 2026 |
| Investor Presentation (October 2026) | Investor deck | 48 slides | October 2026 |
| Fact Sheet (September 2026) | Fact sheet | 5 slides | Sep 30, 2026 |
| H1 2026 Earnings Presentation | Earnings | 38 slides | Jul 30, 2026 |
| Fact Sheet (July 2026) | Fact sheet | 5 slides | Jul 29, 2026 |
| Investor Presentation (July 2026) | Investor deck | 51 slides | July 2026 |
| Technical Presentation (March 2026) | Technical | 23 slides | Mar 31, 2026 |
| Idorsia Pharmaceuticals — Q4 2025 Earnings Presentation | Earnings | 23 slides | Feb 26, 2026 |
| J. P. Morgan Healthcare Conference 2026 | Conference | 23 slides | January 2026 |
Show 50 decks
This page holds 50 of 55 decks. Open Decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| New Notes of Idorsia Investments SARL with 12% earn-out Announced: CHF 72M Use of proceeds: Launch capital for TRYVIO/JERAYGO: a focused US launch and phased commercialization in Europe and Canada | Oct 29, 2026 | US$86.78M |
| Private placement of registered shares (new and treasury shares) Closed: CHF 65.6M raised · CHF 4 a share Buyers: Jean-Paul and Martine Clozel (Offer Shares for an aggregate amount of up to CHF 10 million) Insiders: Founding shareholders Jean-Paul and Martine Clozel committed to buy Offer Shares at the offer price for up to CHF 10 million, with a 180-day lockup Use of proceeds: Strengthen balance sheet, accelerate QUVIVIQ commercial trajectory, advance pipeline, and general corporate purposes | Oct 10, 2025 | US$81.69M |
| Shares (equity line) Update: raise Use of proceeds: To further extend the cash runway into 2027 | Aug 27, 2025 | |
| New money facility Update: CHF 150M · Warrants at CHF 1.5 Use of proceeds: Extend cash runway to mid-2026 | May 21, 2025 | US$181.85M |
| Private placement of shares Announced: private placement Use of proceeds: Additional capital to meet its obligations | Feb 26, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CHF
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 221.0M | 112.5M | 152.4M | 97.1M | 35.3M | 71.8M | 23.8M | 60.6M | 158.1M | 0 |
| Cost of revenue | 38.4M | 179.6M | 7.15M | 6.27M | 18.0M | 381.1M | 438.5M | 370.1M | 161.9M | 18.1M |
| Gross profit | 182.2M | -67.1M | 145.2M | 90.8M | 17.3M | -309.3M | -414.7M | -309.5M | -3.81M | -18.1M |
| Research and development | 100.9M | 143.7M | 293.6M | 383.3M | 414.2M | 381.1M | 438.5M | 370.1M | 134.9M | 282.6M |
| Selling, general and administrative | 221.3M | 231.7M | 380.0M | 333.9M | 233.7M | 63.0M | 49.0M | 60.6M | 37.1M | 40.2M |
| Operating income | -131.0M | -232.0M | -255.1M | -803.0M | -613.0M | -410.6M | -482.4M | -371.1M | -7.88M | -322.8M |
| Depreciation and amortization | 17.4M | 17.9M | 19.0M | 19.8M | 18.0M | 18.9M | 19.7M | 19.6M | 10.1M | 18.1M |
| EBITDA | -113.6M | -214.1M | -236.1M | -783.1M | -595.0M | -391.7M | -462.7M | -351.5M | 2.17M | -304.7M |
| Interest expense | 42.6M | 20.1M | 20.7M | 17.2M | 27.9M | 9.72M | 8.16M | 16.8M | 7.21M | 13.4M |
| Income before tax | -105.6M | -263.3M | -294.3M | -820.1M | -634.8M | -449.3M | -485.2M | -387.8M | -15.1M | -336.7M |
| Income tax | 6.12M | 434.0K | 3.67M | 7.81M | -210.0K | -4.16M | 9.45M | -314.0K | 186.0K | -2.05M |
| Net income | -112.0M | -263.8M | -297.9M | -827.9M | -634.6M | -445.1M | -494.6M | -386.4M | -14.3M | -335.1M |
| Earnings per share, basic | -0.52 | -1.45 | -1.67 | -4.67 | -3.77 | -3.12 | -3.72 | -3.06 | -0.12 | -2.78 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 87.2M | 106.4M | 145.1M | 146.0M | 101.4M | 140.8M | 263.0M | 798.6M | 622.5M | 728.0M |
| Short-term investments | 18.0M | 12.8M | 330.3M | 936.8M | 869.2M | 480.1M | 125.1M | 218.3M | ||
| Receivables | 51.9M | 26.4M | 20.3M | 49.3M | 16.7M | 10.6M | 14.3M | 6.79M | 20.2M | 2.85M |
| Inventory | 82.1M | 62.6M | 59.1M | 35.8M | 21.7M | 12.9M | 17.7M | 10.6M | -23.2M | 0 |
| Current assets | 223.8M | 255.5M | 276.3M | 596.4M | 1.08B | 1.03B | 775.4M | 941.4M | 881.3M | 753.2M |
| Property, plant and equipment | 190.9M | 216.9M | 209.7M | 245.5M | 223.4M | 196.2M | 206.7M | 150.7M | 156.7M | 158.4M |
| Goodwill | 0 | |||||||||
| Total assets | 465.9M | 505.9M | 500.0M | 904.2M | 1.48B | 1.44B | 1.00B | 1.41B | 1.29B | 915.1M |
| Accounts payable | 17.5M | 35.2M | 19.9M | 25.4M | 26.9M | 11.1M | 8.76M | 7.13M | 4.25M | 10.7M |
| Current liabilities | 160.9M | 443.2M | 301.3M | 170.4M | 165.1M | 127.5M | 110.9M | 104.9M | 93.2M | 65.9M |
| Long-term debt | 1.15B | 931.8M | 931.0M | 1.13B | 1.09B | 587.4M | 579.0M | 570.8M | 364.7M | 293.4M |
| Total debt | 1.27B | 1.26B | 1.20B | 1.23B | 1.16B | 638.0M | 643.3M | 570.8M | 364.7M | 293.4M |
| Total liabilities | 1.60B | 1.72B | 1.47B | 1.57B | 1.38B | 849.9M | 839.9M | 749.1M | 552.4M | 407.2M |
| Shareholders' equity | -1.14B | -1.21B | -968.7M | -661.0M | 104.2M | 585.5M | 172.4M | 664.7M | 745.4M | 512.3M |
| Shares outstanding | 214.7M | 182.4M | 178.2M | 177.4M | 168.5M | 142.8M | 132.9M | 126.5M | 115.5M | 120.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -153.2M | -370.2M | -629.3M | -859.1M | -589.9M | -364.7M | -462.0M | -352.8M | 95.5M | -263.3M |
| Capital spending | -13.8M | -3.00M | -9.40M | -27.1M | -30.9M | -9.29M | -19.0M | -14.3M | -7.66M | -8.68M |
| Free cash flow | -167.0M | -373.2M | -638.7M | -886.2M | -620.8M | -374.0M | -481.0M | -367.1M | 87.8M | -272.0M |
| Cash from investing | 4.16M | 305.1M | 632.6M | 743.9M | -53.3M | -607.1M | -74.8M | 31.2M | -476.0M | -8.68M |
| Cash from financing | 132.1M | 26.1M | -197.0K | 162.3M | 604.1M | 850.1M | 1.33M | 497.8M | 1.00B | 1.20B |
| Dividends paid | -594.6M | |||||||||
| Share buybacks | 84.4M | -80.0K | -197.0K | 360.0K | -418.0K | 850.1M | 1.33M | 299.4M | 6.44M | 6.44M |
| Change in cash | -17.8M | -38.7M | -946.0K | 44.6M | -39.5M | -122.2M | -535.5M | 176.1M | 622.5M | -272.0M |
Cap table
Built by 6ix from Idorsia Ltd.’s releases · as of Oct 29, 2026
- Common shares
- 269,779,588
- Fully diluted
- 269,779,588
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 269,779,588 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 269,779,588 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Amer Joseph | Executive Vice President, Chief Medical Officer & Head of Global Clinical Development · Since May 1, 2026 |
| Arno Groenewoud | Executive Vice President, Chief Financial Officer · Since at least Oct 29, 2026 |
| Benjamin Limal | Executive Vice President, President of Europe & International Markets Region · Since at least Jul 27, 2026 |
| Dominique Le Terrier | Executive Vice President, Head of Global Commercial Strategy & New Product Planning · Since at least Nov 5, 2026 |
| Jean-Paul Clozel | Chairman of the Board · Since at least Aug 11, 2026 |
| Julien Gander | Executive Vice President, Chief Legal & Corporate Development Officer · Since at least Nov 5, 2026 |
| Kevin Boss | Director, Investor Relations · Since at least Oct 29, 2026 |
| Martine Clozel | Executive Vice President, Chief Scientific Officer & Head of Research · Since at least Jun 1, 2026 |
| Mathieu Simon | Vice-Chairman and Lead Independent Director · Since at least May 6, 2026 |
| Roland Wandeler | Chief Executive Officer · Since Oct 1, 2026 |
Log in to ask 6ix AI your own questions about Idorsia Ltd.